The role of Fas/FasL in immunosuppression induced by human tumors

Cancer Immunology Immunotherapy

Volumn 46, Issue 4, 1998, Pages 175-184

  Whiteside, Theresa L ^a,b   Rabinowich, Hannah ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; TUMOR ANTIGEN;

APOPTOSIS; CARCINOGENESIS; EFFECTOR CELL; IMMUNE DEFICIENCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY;

ANTIGENS, CD95; FAS LIGAND PROTEIN; HUMANS; IMMUNE TOLERANCE; MEMBRANE GLYCOPROTEINS; NEOPLASMS;

EID: 0031747564     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050476     Document Type: Review

References (90)

1. 2. J Immunol 153: 1674-1685
2. Anichini A, Fossati G, Parmiani G (1985) Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma. Int J Cancer 35:683-689
3. Aoe T, Okamoto Y, Saito T (1995) Activated macrophages include structural abnormalities of the T-cell receptor-CD3 complex. J Exp Med 181:1881-1886
4. Berke G (1995) The CTL's kiss of death. Cell 81:9-11
5. Broder S, Waldmann TA (1978) The suppressor cell network in cancer. N Engl J Med 299:1281-1286
6. Cai Z, Stancou R, Korner M, Chouaib S (1996) Impairment of Fas-antigen expression in Adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int J Cancer 68:535-546
7. Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R (1985) Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 230:453-455
8. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM (1997) Enhancement of cellular immunity in melanoma pateints immunized with a peptide from MART-1/Melan-A. Cancer J Sci Am 3:37-44
9. D'Andrea A, Aste-Amezaga M, Valiante NM, Max, Kubin M, Trinchieri G (1993) Interleukin 10 (IL-10) inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178:1041-1048
10. DeMaria R, Lenti L, Malisan F, d'Agostino F, Tomassini B, Zeuner A, Rippo MR, Testi R (1997) Requirement for GD3 ganglioside in CD95-and ceramide-induced apoptosis. Science 277:1652-1655
11. Deveraux, QL, Takahashi, R, Salvesen, GS, Reed, JC (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300-304
12. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E, Birkenbach M (1996) A novel interleukin-12 p40-mediated protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 70:1143-1153
13. Droge W, Schultze-Osthoff K, Mihm S, Galter D, Schenk H, Eck HP, Roth S, Gmunder H (1994) Functions of glutathione and glutathione disulfide in immunology and immunotherapy. FASEB J 8:1131-1138
14. Ebert EC, Roberts AI, O'Connell SM, Robertson FM, Nagase H (1987) Characterization of an immunosuppressive factor derived from colon cancer cell. J Immunol 138:2161-2168
15. lck in T-cell infiltrating human renal cell carcinoma. Cancer Res 53: 5613-5616
16. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815-3822
17. Fox FE, Capocasale RJ, Ford HC, Lamb RJ, Moore JS, Nowell PC (1992) Transforming growth factor-β inhibits human T-cell proliferation through multiple targets. Lymphokine Cytokine Res 11:299-305
18. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM (1997) The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57:3823-3829
19. Ghosh P, Sica A, Young HA, Ye J, Franco JL, Wiltrout RH, Longo DL, Rice NR, Komschlies KL (1994) Alterations in NFκB/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 54:2969-2972
20. Griffith TS, Ferguson TA (1997) The role of FasL-induced apoptosis in immune privilege. Immunol Today 18:240-244
21. Gunji Y, Hori S, Aoe T, Asano T, Ochiai T, Isono K, Saito T (1994) High frequency of patients with abnormal assembly of T cell receptor-CD3 complex in peripheral blood T lymphocytes. Jpn J Cancer Res 85:1189-1192
22. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier LE, French P, Schneider T, Bornand A, Fontana A, Lienard D, Cerottini J-C, Tschopp J (1996) Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366
23. Haraguchi S, Good RA, James-Yarish M, Cianciolo GJ, Day NK (1995) Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein. Immunology 92:3611-3615
24. Hersh EM, Drewinko B (1974) Specific inhibition of lymphocyte blastogenic response to mitogens by a factor produced by cultured human malignant lymphoma cells. Cancer Res 34:215-220
25. Hersh EM, Oppenheim JJ (1965) Impaired in vitro lymphocyte transformation in Hodgkin's disease. N Engl J Med 273: 1006-1012
26. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, Fusamoto H, Kamada T (1994) Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 19:1354-1359
27. Hu SM, Vincenz C, Ni J, Gentz R and Dixit VM (1997) I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD95-induced apoptosis. J Biol Chem 272:17255-17257
28. Irmler M, Thome M, Hahne M, Schneider P, Hoffman K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:17255-17257
29. Jaeger E, Bernahrd H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M, Knuth A (1996) Generation of cytotoxic T-cell responses with synthetic peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66:162-169
30. + T lymphocytes. Science 256:1452-1456
31. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Res 56:4791-4798
32. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S (1997) Essential roles of the Fas ligand in the development of hepatitis. Nat Med 3:409-413
33. Kono K, Onfay-Salazar F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R (1996) Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell and natural killer cell-mediated cytotoxicity. Eur J Immunol 26:1308-1313
34. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL (1996) Alterations in expression and function of signal transduction proteins in tumor associated NK and T lymphocytes from patients with ovarian carcinoma. Clin Cancer Res 2:161-173
35. lyn, ZAP-70, and CD3ζ despite suppressed cytolytic activity. J Exp Med 182:1029-1036
36. Li X, Liu J, Park J-K, Hamilton TA, Rayman P, Klein E, Edinger M, Tubbs RR, Bukowski R, Finke J (1994) T cells from renal cell carcinoma patients exhibit an abnormal patttern of κB specific DNA binding activity. Cancer Res 54:5424-5429
37. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE, MacKenzie A and Korneluk RG (1996) Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 379:349-353
38. Lopez DM, Lopez-Cepero M, Watson GA, Ganju A, Sotomayor E, Fu YX (1991) Modulation of the immune system by mammary tumor-derived factors. Cancer Invest 9:643-653
39. Mannick JB, Miao XQ, Stamler JS (1997) Nitric oxide inhibits Fas-induced apoptosis. J Biol Chem 272:24 125-24 128
40. Matsuda M, Petersson M, Lenkei R, Raupin J-L, Magnusson I, Mellstedt H, Anderson P, Kiessling R (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61:765-772
41. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitral M-T (1997) Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 89:783-789
42. Miescher S, Whiteside TL, Carrell S, Fliedner V von (1986) Functional properties of tumor infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899-1907
43. Miescher S, Whiteside TL, Moretta L, Fliedner V von (1987) Clonal and frequency analysis of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 138:4004-4011
44. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, Fliedner V von (1988) Preferential clonogenic deficit of CD8+ T lymphocytes infiltrating human solid tumors. Cancer Res 48:6992-6998
45. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, Fliedner V von (1988) Proliferation and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer 42:659-666
46. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa A (1992) Alterations in signal transduction molecules in T lymphocytes from tumor hearing mice. Science 258:1795-1798
47. Mizutani Y, Okada Y, Yoshida O, Fukumoto M, Bonavida B (1997) Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer 79:1180-1189
48. Moy PM, Holmes EC, Golub SH (1985) Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res 45:57-60
49. Mukherji B, MacAlister TJ (1983) Clonal analysis of cytotoxic T-cell response against human melanoma. J Exp Med 158:240-245
50. Nagata S, Goldstein P (1995) The Fas death factor. Science 267:1449-1456
51. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J-L, Vivier E, Anderson P, Kiessling R (1993) Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cell and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610-5612
52. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Kanpp DJ, Green DR, Kratzke RA (1997) Human lung carcinomas express fas ligand. Cancer Res 57:1007-1012
53. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075-1082
54. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F (1997) The fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 3:294-300
55. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effects of the anti-Fas antibody in mice. Nature 364:806-809
56. Oliver RT, Nouri AM (1992) T cell immune responses to cancer in humans and its relevance for immunodiagnosis and therapy. Cancer Surv 13:173-180
57. Piali L, Fichtel A, Terpe H-J, Imhof BA, Gisler RH (1995) Endothelial vascular adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 181:811-816
58. Rabinowich H, Banks M, Reichert T, Logan TF, Kirkwood JM, Whiteside TL (1996) Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after IL-2 therapy. Clin Cancer Res 2: 1263-1274
59. Rabinowich H, Suminami Y, Reichert TE, Crowley-Nowick P, Bell M, Edwards R, Whiteside TL (1996) Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 68:276-284
60. Rabinowich H, Reichert TE, Kashii Y, Bell MC, Whiteside TL (1998) Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of TcR in tumor-associated lymphocytes J Clin Invest (in press)
61. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL (1997) Human immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J Immunother (in press)
62. Rodriguez I, Matsuura K, Ody C, Nagata S, Vassalli P (1996) Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated tulminant liver destruction and death. J Exp Med 184:2067-2072
63. Rokhlin OW, Hostager BS, Bishop GA, Sidorenko SP, Glover RA, Gudkov AV, Cohen MB (1997) Dominant nature of the resistance to Fas-and tumor necrosis factor-α-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 57:3941-3943
64. Roth JA, Grimm EA, Gupta RK, Ames RS (1982) Immunoregulatory factors derived from human tumors. J Immunol 128: 1955-1962
65. Roth JA, Osborne BA, Ames RS (1983) Immunoregulatory factors derived from human tumors. II. Partial purification and further immunobiochemical characterization of a human sarcome-derived immunosuppressive factor expressing HLA-DR and immunoglobulin-related determinants. J Immunol 130:303-308
66. Roth W, Fontana A, Trepel M, Reed J, Dichgans J, Weller M (1997) Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 44:55-63
67. Shimizu Y, Iwatsuki S, Herberman RB, Whiteside TL (1990) Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors. Int J Cancer 46:878-883
68. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H (1997) Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Med Sci 94:6420-6425
69. Stassi G, DeMaria R, Trucco G, Rudert W, Testi R, Galluzzo A, Giordano C, Trucco M (1997) Nitric oxide primes pancreatic B cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 186:1193-1200
70. Stein CA, Cheng Y-C (1993) Antisense oligonucleotides as therepeutic agents - is the bullet really magic? Science 26:1004-1012
71. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells. A mechanism of immune evasion? Nat Med 2: 1361-1366
72. Sulitzeanu D (1993) Immunosuppressive factors in human cancer. Adv Cancer Res 60:247-271
73. Synderman R, Cianciolo GJ (1984) Immunosuppressive activity of the retroviral envelope protein p15E and its possible relationship to neoplasia. Immunol Today 5:240-244
74. Tada T, Dhzeki S, Utsumi K, Takiuchi H, Maramatsu M, Li XF, Shimizu J, Fujiwara H, Hamaoku T (1991) Transforming growth factor-β-induced inhibition of T-cell function. J Immunol 146: 1077-1082
75. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S (1996) Fas ligand in human serum. Nat Med 2:317-322
76. Tineke CTM, Kraan VDP, Boeije LCM, Smeenk RJT, Wijdenes J, Aarden LA (1995) Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 181:775-779
77. Uotila P (1996) The role of cyclic AMP and oxygen intermediates in the inhibititon of cellular immunity in cancer. Cancer Immunol Immunother 43:1-9
78. Vitolo D, Zerbe T, Kanbour A, Dahl C, Herberman RB, Whiteside TL (1992) Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 51:573-580
79. Vitolo D, Kanbour A, Johnson JT, Herberman RB, Whiteside TL (1993) In situ hybridization for cytokine gene transcripts in the solid tumor microenvironment. Eur J Cancer 29A:371-377
80. Vose BM, White W Tumor-reactive lymphocytes stimulated in mixed lymphocyte and tumor culture (1983) Clonal analysis of effector cells in cytotoxic and proliferative assays. Cancer Immunol Immunother 15:227-236
81. Walker PR, Saas P, Dietrich PY (1997) Role of Fas ligand (CDS95L) in immune escape: the tumor cell strikes back. J Immunol 158:4521-4524
82. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A (1994) Anti-Fas/APO-1 mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 94:954-964
83. Whiteside TL (1992) Tumor-infiltrating lymphocytes as antitumor effector cells. Biotherapy 5:47-61
84. Whiteside TL (1993) Tumor-infiltrating lymphocytes in human malignancies. Landes, Austin, Tex
85. Whiteside TL, Parmiani G (1994) Tumor-infiltrating lymphocytes: their phenotype, function and clinical use. Cancer Immunol Immunother 39:15-21
86. Whiteside TL, Miescher S, Hurlimann J, von Fliedner V (1986) Separation, phenotyping and limiting-dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer 37:803-811
87. Wrann M, Bodmer S, Martin R de, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A (1987) T-cell suppressor factor from human glioblastoma cells is a 12.5 Kd protein closely related to transforming growth factor β. EMBO J 138:2161-2168
88. Yasumura S, Lin W-c, Hirabayashi H, Vujanovic NL, Herberman RB, Whiteside TL (1994) Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells. Cancer Res 54:3808-3816
89. Zea AH, Cutri BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ, Ochoa AC (1995) Alterations in T cell receptor and signal transduction molecules in melanoma pateints. Clin Cancer Res 1:1327-1335
90. Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti P (1997) Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood 90:1952-1959